← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Virogenomics, Inc.
Portland, OR
$8,754,638
Total funding
25
Grants
Funding over time
peak $1.6M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$7,987,252 · 23
NSF$767,386 · 2
By mechanism
R42$4,330,926 · 5
R41$2,502,483 · 13
R43$1,153,843 · 5
—$767,386 · 2
Investigators at Virogenomics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Novel Intervention Strategy for Stroke with RTL Therapy$681,615
R42 · FY2012 · NS
A Novel Intervention Strategy for Stroke with RTL Therapy$668,668
R42 · FY2013 · NS
SBIR Phase II: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support$587,394
· FY2012 · TIP
Recombinant T Cell Receptor Ligands for Treatmentof Uveitis$382,025
R42 · FY2009 · EY
Osteopontin, a Novel Neuroprotectant in Brain Ischemia$376,909
R42 · FY2006 · NS
HLA-DQ-derived RTLs for Treatment of Celiac Disease$376,680
R42 · FY2007 · DK
Recombinant T Cell Receptor Ligands for Treatmentof Uveitis$375,338
R42 · FY2010 · EY
Osteopontin, a Novel Neuroprotectant in Brain Ischemia$374,807
R42 · FY2005 · NS
HLA-DQ-derived RTLs for Treatment of Celiac Disease$374,744
R42 · FY2006 · DK
Development of a T cell specific multiple sclerosis drug$361,013
R42 · FY2004 · NS
Development of a T cell specific multiple sclerosis drug$359,127
R42 · FY2005 · NS
Development of Novel Small Molecule Flavivirus Inhibitors$301,727
R41 · FY2010 · AI
Development of Novel Small Molecule Flavivirus Inhibitors$300,318
R41 · FY2009 · AI
Genetically Defined Attenuated Living Vaccine for Francisella$298,617
R41 · FY2008 · AI
Development of a plant-grown subunit vaccine against respiratory syncytial virus$290,747
R43 · FY2011 · AI
Development of a plant-grown subunit vaccine against respiratory syncytial virus$290,321
R43 · FY2010 · AI
Genetically Defined Attenuated Living Vaccine for Francisella$289,487
R41 · FY2007 · AI
Electrochemical diagnostics for rapid, multiplexed detection of RA biomarkers$281,496
R43 · FY2012 · AR
SBIR Phase I: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support$179,992
· FY2010 · TIP
Novel RTL treatment to promote brain repair and cognitive recovery following meth$173,244
R41 · FY2010 · DA